Classifications: anticholinergic; antispasmodic; Therapeutic: urinary tract antispasmodic
Pregnancy Category: C
100 mg tablets
Exerts spasmolytic (papaverine-like) action on smooth muscle. Reported to produce an increase in urinary bladder capacity
in patients with spastic bladder, possibly by direct action on detrusor muscle. Also demonstrates local anesthetic and analgesic
Has antispasmodic action on the urinary bladder.
Symptomatic relief of dysuria, frequency, urgency, nocturia, incontinence, and suprapubic pain associated with various urologic
Pyloric or duodenal obstruction, obstructive intestinal lesions, ileus, achalasia, GI hemorrhage; obstructive uropathies of
lower urinary tract; pregnancy (category C). Safety in children <12 y is not established.
Elderly; suspected or closed-angle glaucoma; myasthenia gravis; autonomic neuropathy; dehydration.
Route & Dosage
|Dysuria, Nocturia, Incontinence
Adult: PO 100200 mg t.i.d. or q.i.d.
- Give without regard to meals.
- Store at 15°30° C (59°86° F) unless otherwise directed.
Adverse Effects (≥1%)CNS:
Headache, vertigo, drowsiness, mental confusion (especially in older adults). CV:
Palpitation, tachycardia. Special Senses:
Blurred vision, increased intraocular tension, disturbances of eye accommodation. GI:
Nausea, vomiting, dry mouth (and throat), constipation
(with high doses). Skin:
Dermatosis, urticaria. Other:
Dysuria, hyperpyrexia, eosinophilia, leukopenia (rare).
May antagonize the GI motility effects of metoclopramide.
1030% in urine within 6 h.
Assessment & Drug Effects
- Monitor heart rate. Take apical pulse for 1 full minute. Report tachycardia.
- Lab tests: Obtain periodic evaluation of blood counts during therapy.
Patient & Family Education
- Do not drive or engage in potentially hazardous activities until response to drug is known.
- Report adverse reactions to physician as well as clinical improvement or the lack of a favorable response.